Sun Pharmaceutical Quarterly Results for Trading Insights
In Mar 2026, Sun Pharmaceutical (SUNPHARMA) reported revenue ₹15,018 Cr and net profit ₹2,710 Cr — revenue +11.8% YoY. For annual financials, live price and key ratios, visit Sun Pharmaceutical stock price NSE.
SUNPHARMA Quarterly Results — Revenue, Profit & EPS Highlights
Sun Pharmaceutical latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Compare with SUNPHARMA fair value estimate to assess whether the stock is under or overvalued.
- Revenue of ₹15,018 Cr in Mar 2026 (+1.0% vs Sept 2025, +11.8% vs Mar 2025)
- Net Profit of ₹2,710 Cr in Mar 2026 (-13.3% vs Sept 2025, +25.8% vs Mar 2025)
- EBITDA of ₹4,361 Cr in Mar 2026 (-11.4% vs Sept 2025)
- Operating Margin of 27.0% in Mar 2026 (-4.0pp vs Sept 2025)
- Earnings Per Share of ₹11.30 in Mar 2026 (-13.1% vs Sept 2025)
Sun Pharmaceutical Quarterly Results — Revenue, EBITDA, Net Profit & EPS
SUNPHARMA quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 15,018 | 14,875 | 13,429 | 14,251 | 16,048 | 1.0% | 11.8% |
| Net Profit (₹ Cr) | 2,710 | 3,125 | 2,154 | 2,293 | 3,381 | - | - |
| EBITDA (₹ Cr) | 4,361 | 4,924 | 3,824 | 3,883 | 4,986 | - | - |
| EPS (₹) | 11.30 | 13.00 | 9.00 | 9.50 | 14.00 | - | - |
| Operating Margin (%) | 27.0% | 31.0% | 25.0% | 25.0% | 28.0% | - | - |
SUNPHARMA Share Price Trend — 1-Year Movement Across Quarterly Results
Sun Pharmaceutical 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Also explore SUNPHARMA stock price history to track price trends across different timeframes.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
SUNPHARMA vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Sun Pharmaceutical latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Divis Laboratories
Mar 2026 |
₹180,186.80 Cr | 6713.5 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 237.1 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹152,449.36 Cr | 4516.2 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 392.4 |
|
Cipla
Mar 2026 |
₹116,150.78 Cr | 1440.1 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 209.6 |
|
Dr Reddys Laborator…
Mar 2026 |
₹110,873.98 Cr | 1350.5 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 509.6 |
|
Zydus Life Science
Mar 2026 |
₹109,226.70 Cr | 1101.4 | 7,569 | 1,341 | +23.1% | +18.8% | 17.7% | 87.1 |
All amounts in ₹ Crores